Home
News
Screeners
Insights
Accretion Nutraveda
270.
00
-12.00
(-4.26%)
Market Cap
₹195.51 Cr
PE Ratio
-
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-4.26%
1M
-9.70%
6M
0.00%
1Y
0.00%
5Y
0.00%
View Company Insights
Latest news about Accretion Nutraveda
Accretion Nutraveda seeks ₹500 crore borrowing limit via postal ballot
3 days ago
Accretion Nutraveda seeks approval to raise borrowing limits to ₹500 crore. Shareholders to vote on altering MOA to expand business objects. E-voting period runs from September 10 to October 9, 2026. Board proposes ₹100 crore limit for loans to subsidiaries and investments.
Accretion Nutraveda board approves MOA alteration, borrowing limits
10 days ago
Accretion Nutraveda AGM resolutions pass with unanimous shareholder support
Aug 27, 2026
Accretion Nutraveda to seek approval for director appointments, pay hikes at AGM
Aug 05, 2026
Accretion Nutraveda FY26 Results: Revenue Jumps 110%, PAT Surges 103%
Aug 05, 2026
More news about Accretion Nutraveda
01
May 26
Accretion Nutraveda Limited Schedules Board Meeting for May 8, 2026 to Approve FY26 Financial Results
Accretion Nutraveda Limited has scheduled a Board of Directors meeting for May 8, 2026, to consider and approve audited financial results for the year ended March 31, 2026. The company communicated this intimation to BSE Limited on May 1, 2026, complying with Regulation 29 of SEBI LODR 2015. The meeting represents standard corporate governance practice for the BSE-listed company with scrip code 544694.
04
Apr 26
Accretion Nutraveda Limited Files SEBI Compliance Certificate for Q4FY26
Accretion Nutraveda Limited submitted its mandatory SEBI compliance certificate for Q4FY26, confirming all company shares remained in dematerialized form during the quarter ended 31st March, 2026. The certificate, issued by registrar KFin Technologies Limited under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018, reported no rematerialization requests during the period. This regulatory filing maintains the company's transparency obligations and demonstrates continued compliance with SEBI depositories regulations.
01
Apr 26
Accretion Nutraveda Limited Updates Corporate Identification Number Following BSE SME Listing
Accretion Nutraveda Limited has notified BSE Limited about the update of its Corporate Identification Number from U24290GJ2021PLC121216 to L24290GJ2021PLC121216, following its equity shares listing on BSE SME Exchange on 04th February, 2026. The Gujarat-based company, incorporated in 2021, maintains an authorised capital of ₹8,00,00,000 and paid-up capital of ₹7,24,00,000. The CIN update was processed by the Ministry of Corporate Affairs as part of the post-listing regulatory requirements.
26
Mar 26
Accretion Nutraveda Limited Appoints KMV & Co as Internal Auditor and Authorizes Key Personnel for SEBI Disclosures
Accretion Nutraveda Limited's board meeting on March 26, 2026 resulted in the appointment of M/s. KMV & Co., Chartered Accountants as Internal Auditor and authorization of key managerial personnel for SEBI compliance. The firm brings expertise in audit, taxation, and outsourcing services with presence across multiple cities.
Accretion Nutraveda
270.
00
-
12.
00
(-
4.
26
%)
1 Year Returns:
0.00%
Industry Peers
Sun Pharmaceutical
1,840.00
(-
1.
13
%)
Divis Laboratories
9,322.00
(-
1.
23
%)
Torrent Pharmaceuticals
4,965.50
(+
0.
72
%)
Zydus Life Science
1,119.10
(+
0.
12
%)
Cipla
1,366.00
(-
0.
53
%)
Laurus Labs
1,969.00
(+
1.
23
%)
Dr Reddys Laboratories
1,165.50
(+
1.
97
%)
Aurobindo Pharma
1,679.80
(+
0.
68
%)
Lupin
2,095.00
(+
0.
83
%)
Mankind Pharma
2,280.00
(+
1.
86
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar